Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aroa BiosurgeryASX:ARX -2.63%57 Debt-to-Equity is 0.06 as of Mar. 2026, which is 14% below its 10-year median of 0.07. GuruFocus rates ASX:ARX with a GF Score™ of 57/100 and a GF Value™ of A$0.82 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 706 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 77.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Aroa Biosurgery's Debt-to-Equity or its related term are showing as below:
ASX:ARX'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.06 Med: 0.07 Max: 0.28
Current: 0.06
During the past 7 years, the highest Debt-to-Equity Ratio of Aroa Biosurgery was 0.28. The lowest was 0.06. And the median was 0.07.
ASX:ARX's Debt-to-Equity is ranked better than 77.9% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ASX:ARX: 0.06
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Aroa Biosurgery Debt-to-Equity Related Terms
Aroa Biosurgery Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Aroa Biosurgery's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ARX vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Aroa Biosurgery's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aroa Biosurgery Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Aroa Biosurgery's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aroa Biosurgery (ASX:ARX) has a Debt-to-Equity of 0.06 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aroa Biosurgery and its competitors. This is 14% below median its historical median of 0.07. Over the past decade, Aroa Biosurgery's Debt-to-Equity has ranged from 0.06 to 0.28. According to the industry distribution chart, Aroa Biosurgery ranks #156 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 22.1%.
Is Aroa Biosurgery's Debt-to-Equity too high?
Aroa Biosurgery's current Debt-to-Equity of 0.06 is 14% below median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.28. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Aroa Biosurgery's value of 0.06 is 73.9% below this industry median. Based on the distribution chart, Aroa Biosurgery ranks #156 out of 706 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aroa Biosurgery has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #156 out of 706 companies for Debt-to-Equity. This places Aroa Biosurgery in the top 22% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Aroa Biosurgery's value of 0.06 is 73.9% below this benchmark. Historically, Aroa Biosurgery's own Debt-to-Equity has ranged from 0.06 to 0.28 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 0.23, Aroa Biosurgery has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aroa Biosurgery's current Debt-to-Equity of 0.06 is 73.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Aroa Biosurgery and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aroa Biosurgery's current Debt-to-Equity is 0.06, which is 14% below median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.82, compared to a current price of A$0.56 — trading 32.3% below its estimated fair value. The current Debt-to-Equity is 0.06, which is 14% below median its 10-year median of 0.07 and 73.9% below the Medical Devices & Instruments industry median of 0.23. Aroa Biosurgery's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current Debt-to-Equity is 0.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?
Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued.
The current stock price of A$0.56 is trading 32.3% below its estimated GF Value™ of A$0.82.
GuruFocus considers Aroa Biosurgery to be Significantly Undervalued.
Key valuation signals for ASX:ARX:
Debt-to-Equity: 0.06 (14% below median its 10-year median of 0.07)
GF Value™: A$0.82 vs. price of A$0.56 (32.3% below fair value)
Industry Position: 73.9% below the Medical Devices & Instruments median (#156 of 706)
No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
57GF Score
Get the complete analysis for ASX:ARX
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ARX has been successfully added to your 
